BRCA1 and ovarian cancer: Furthermore, understanding the role of BRCA1/2 variants in ovarian cancer has allowed for the development of targeted therapies, namely PARP (poly[adenosine diphosphate–ribose] polymerase) inhibitors, which improve progression-free survival in selected women with ovarian cancer.